It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
O-linked β-N-acetylglucosaminylation (O-GlcNAcylation) is a reversible post-translational modification on serine and threonine residues of cytosolic, nuclear and mitochondrial proteins. O-GlcNAcylation level is regulated by OGT (O-GlcNAc transferase), which adds GlcNAc on proteins, and OGA (O-GlcNAcase), which removes it. Abnormal level of protein O-GlcNAcylation has been observed in numerous cancer cell types, including cervical cancer cells. In the present study, we have evaluated the effect of increasing protein O-GlcNAcylation on cervical cancer-derived CaSki cells. We observed that pharmacological enhancement of protein O-GlcNAcylation by Thiamet G (an inhibitor of OGA) and glucosamine (which provides UDP-GlcNAc substrate to OGT) increases CaSki cells proliferation, migration and survival. Moreover, we showed that increased O-GlcNAcylation promotes IGF-1 receptor (IGF1R) autophosphorylation, possibly through inhibition of protein tyrosine-phosphatase 1B activity. This was associated with increased IGF-1-induced phosphatidyl-Inositol 3-phosphate production at the plasma membrane and increased Akt activation in CaSki cells. Finally, we showed that protein O-GlcNAcylation and Akt phosphorylation levels were higher in human cervical cancer samples compared to healthy cervix tissues, and a highly positive correlation was observed between O-GlcNAcylation level and Akt phosphorylation in theses tissues. Together, our results indicate that increased O-GlcNAcylation, by activating IGF1R/ Phosphatidyl inositol 3-Kinase (PI-3K)/Akt signaling, may participate in cervical cancer cell growth and proliferation.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 National Technology of Mexico/IT.Oaxaca, Oaxaca, Mexico; Universidad Autónoma Benito Juárez de Oaxaca, Faculty of Medicine and Surgery, Oaxaca, Mexico (GRID:grid.440442.2) (ISNI:0000 0000 9879 5673); Universidad Autónoma Benito Juárez de Oaxaca, Faculty of Dentistry, Oaxaca, Mexico (GRID:grid.440442.2) (ISNI:0000 0000 9879 5673)
2 Universidad Autónoma Benito Juárez de Oaxaca, Faculty of Medicine and Surgery, Oaxaca, Mexico (GRID:grid.440442.2) (ISNI:0000 0000 9879 5673); Universidad Autónoma Benito Juárez de Oaxaca, Faculty of Dentistry, Oaxaca, Mexico (GRID:grid.440442.2) (ISNI:0000 0000 9879 5673)
3 Universidad Nacional Autónoma de México (UNAM), Departamento de Bioquímica, Facultad de Medicina, Mexico City, Mexico (GRID:grid.9486.3) (ISNI:0000 0001 2159 0001)
4 Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico (GRID:grid.416850.e) (ISNI:0000 0001 0698 4037)
5 National Technology of Mexico/IT.Oaxaca, Oaxaca, Mexico (GRID:grid.416850.e)
6 Tecnológico de Estudios Superiores de Huixquilucan, Magdalena Chichicaspa, Mexico (GRID:grid.416850.e)
7 Université Paris Cité, Institut Cochin, INSERM, CNRS, Paris, France (GRID:grid.462098.1) (ISNI:0000 0004 0643 431X)